Acarix
Sweden - MalmöDiagnostics
Focus: Acarix is a Swedish diagnostics company specializing in acoustic cardiac diagnostic devices for non-invasive coronary artery disease assessment. As a public-stage company founded in 2017, it operates in the high-value cardiovascular diagnostics market.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
0
About Acarix
AI assessmentNot HiringNo open roles listed right now. Follow Acarix to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
5 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
CADScor® System
Stable
Growth
Lead marketed product targeting non-invasive coronary artery disease risk stratification in stable angina populations.
Pipeline & Clinical Trials
Help build intelligence for Acarix
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.